A million Americans need this drug. Trump’s deal won’t help enough of them.

13 May 2019 - A donation of HIV prevention drugs from the pharmaceutical giant Gilead could benefit shareholders more than patients. ...

Read more →

Janssen announces submission of new drug application to U.S. FDA for the first monthly, injectable, two drug regimen of rilpivirine and cabotegravir for treatment of HIV

29 April 2019 - If approved, the rilpivirine and cabotegravir regimen would be the first-ever long-acting injectable treatment for adults living ...

Read more →

HIRA puts brakes on Gilead’s AIDS treatment receiving reimbursement

22 March 2019 - The reimbursement plan for Gilead Science Korea’s Biktarvy, an acquired immune deficiency syndrome (AIDS) treatment, has been ...

Read more →

19,000 Australians now using PBS subsidised anti-HIV drugs

25 March 2019 - About 19,000 Australians have taken advantage of anti-HIV drugs in the first two years of groundbreaking ...

Read more →

U.S. FDA accepts sNDAs for Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)

23 January 2019 - Potential new indication would expand use to allow treatment-experienced adults living with HIV-1 whose virus is suppressed ...

Read more →

Decisions relating to the funded brands of some anti-retroviral treatments for HIV

20 December 2018 - PHARMAC is pleased to announce decisions to award sole supply for seven anti-retroviral treatments used in ...

Read more →

FDA announces pilot program with WHO to expedite review of HIV drug applications

30 November 2018 - The U.S. FDA today announced a plan to work with the WHO to pilot a process to ...

Read more →

Proposal to award sole supply and change some anti-retroviral brands

16 October 2018 - PHARMAC is seeking feedback on a proposal to make several changes to funding of anti-retroviral therapies ...

Read more →

Gilead receives approval in Canada for Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for the treatment of HIV-1 infection

12 July 2018 - Gilead Sciences Canada today announced that Health Canada has granted a notice of compliance for Biktarvy (bictegravir ...

Read more →

Rapid rise in anti-HIV PrEP pills linked to drop in condom use

7 June 2018 - PrEP availability may play a part in men’s complacency about the chances of becoming infected, study suggests. ...

Read more →

New medicine to help end the transmission of HIV

21 March 2018 - The Australian Government is taking a critical step in helping end the transmission of HIV infection in ...

Read more →

National PreP service would be cost effective, research finds

20 October 2017 - Providing pre-exposure prophylaxis treatment to men who have sex with men at high risk of contracting ...

Read more →

TGA approves Odefsey

30 August 2016 - The TGA has approved Gilead's combination product for HIV-1 infection Odefsey. ...

Read more →

Janssen submits marketing authorisation application for darunavir-based single tablet regimen for treatment of HIV-1 to European Medicines Agency

12 September 2016 - Janssen today announced the submission of a Marketing Authorisation Application to the EMA, seeking approval for ...

Read more →

Proposal relating to two HIV treatments (Tivicay and Kivexa)

9 September 2016 - PHARMAC is seeking feedback on a proposal to list a new treatment for HIV, dolutegravir (Tivicay) and ...

Read more →